- Home
- OMER vs UHG Comparison
OMER vs UHG Comparison
Compare OMER & UHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- UHG
- Stock Information
- Founded
- OMER 1994
- UHG 2004
- Country
- OMER United States
- UHG United States
- Employees
- OMER N/A
- UHG N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- UHG Homebuilding
- Sector
- OMER Health Care
- UHG Consumer Discretionary
- Exchange
- OMER Nasdaq
- UHG Nasdaq
- Market Cap
- OMER 188.1M
- UHG 158.8M
- IPO Year
- OMER 2009
- UHG N/A
- Fundamental
- Price
- OMER $3.65
- UHG $3.14
- Analyst Decision
- OMER Strong Buy
- UHG
- Analyst Count
- OMER 5
- UHG 0
- Target Price
- OMER $18.00
- UHG N/A
- AVG Volume (30 Days)
- OMER 936.6K
- UHG 231.7K
- Earning Date
- OMER 08-06-2025
- UHG 08-07-2025
- Dividend Yield
- OMER N/A
- UHG N/A
- EPS Growth
- OMER N/A
- UHG N/A
- EPS
- OMER N/A
- UHG 0.76
- Revenue
- OMER N/A
- UHG $449,877,017.00
- Revenue This Year
- OMER N/A
- UHG N/A
- Revenue Next Year
- OMER $468.75
- UHG N/A
- P/E Ratio
- OMER N/A
- UHG $4.06
- Revenue Growth
- OMER N/A
- UHG 5.24
- 52 Week Low
- OMER $2.95
- UHG $1.60
- 52 Week High
- OMER $13.60
- UHG $6.93
- Technical
- Relative Strength Index (RSI)
- OMER 54.74
- UHG 49.50
- Support Level
- OMER $3.00
- UHG $2.71
- Resistance Level
- OMER $3.25
- UHG $2.95
- Average True Range (ATR)
- OMER 0.24
- UHG 0.33
- MACD
- OMER 0.10
- UHG -0.07
- Stochastic Oscillator
- OMER 83.33
- UHG 28.24
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.